🇮🇳India
अनुदान बजट ओवररन
2 verified sources
Definition
Grant recipients face cost sharing mandates (e.g., 50% for national labs on projects >₹80 lakh) and strict budget heads (equipment, manpower). Manual processes cause undetected overruns, especially with revised estimates showing cuts (e.g., DST R&D from ₹592 crore to ₹200 crore).[2][4]
Key Findings
- Financial Impact: ₹10-20 लाख per project overrun; 50% cost sharing on >₹80 lakh projects
- Frequency: Per grant cycle (18-36 months)
- Root Cause: Manual budget tracking without real-time visibility into scheme-specific allocations
Why This Matters
This pain point represents a significant opportunity for B2B solutions targeting Biotechnology Research.
Affected Stakeholders
Project PI, Finance Officer, Grant Administrator
Action Plan
Run AI-powered research on this problem. Each action generates a detailed report with sources.
Methodology & Sources
Data collected via OSINT from regulatory filings, industry audits, and verified case studies.
Related Business Risks
अनुदान रिपोर्टिंग अनुपालन दंड
₹5-15 लाख fund withholding per delayed report; typical 10-20% grant clawback
अनुदान ट्रैकिंग क्षमता हानि
20-40 hours/month per project (₹5,000-10,000/hour researcher cost)
प्रोटोकॉल विकास में अतिरिक्त ओवरटाइम लागत
40-80 hours overtime per protocol at ₹2,000/hour = ₹80,000-1.6 लाख + consultant fees ₹10-20 लाख[1][3]
EC स्वीकृति रुकावट से क्षमता हानि
30-90 days idle site capacity at ₹1-2 लाख/day = ₹30-180 लाख per trial[1]
अनुमोदन योजना की दृश्यमानता में कमी (Poor Regulatory Approval Visibility)
Estimated ₹1–2 crore annual opportunity cost per biotech firm due to misdirected R&D spending on stalled products and delayed portfolio shifts; 10–15% capital misallocation estimated across Indian biotech sector (₹50–100 crore aggregate annually for sector).